Exelixis (EXEL) Set to Announce Earnings on Tuesday

Exelixis (NASDAQ:EXEL) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.28 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The company had revenue of $479.65 million for the quarter, compared to analyst estimates of $481.23 million. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Trading Up 0.7 %

NASDAQ:EXEL opened at $23.70 on Friday. Exelixis has a 1 year low of $18.08 and a 1 year high of $24.34. The firm has a 50 day moving average of $22.80 and a 200-day moving average of $22.19. The stock has a market capitalization of $6.99 billion, a P/E ratio of 37.03, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada boosted their price target on shares of Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Stifel Nicolaus upped their price objective on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a report on Friday, February 2nd. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. William Blair restated an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Finally, Barclays lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target for the company. in a report on Thursday, April 11th. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus target price of $26.29.

Insider Activity at Exelixis

In related news, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director David Edward Johnson bought 190,000 shares of the stock in a transaction on Wednesday, February 21st. The stock was bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the acquisition, the director now directly owns 1,100,730 shares in the company, valued at $22,785,111. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan M. Garber sold 19,205 shares of the firm’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the sale, the director now directly owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by corporate insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.